Updates in Treatment of HER2-positive Metastatic Breast Cancer
Current Treatment Options in Oncology · 2024-12 · 25 (12) · 1471-1481
DOI: 10.1007/s11864-024-01277-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 09.11.2024. Verfasst von Alzira R M Avelino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
OPINION STATEMENT: The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal antibody. While the first line treatment has remained a combination of dual HER2 blockade with taxane chemotherapy, we now have several exciting options in the second line and beyond. The introduction of antibody-drug conjugates, in specific trastuzumab deruxtecan, has resulted in the best progression-free survival among patients with this subtype of breast cancer. Given the excellent outcomes of these drugs, clinical trials are now evaluating the role of ADCs in the front-line setting in previously untreated patients. In addition, there are also clinical trials evaluating the role of other targets in patients with HER2-positive cancers, including PI3KCA mutations, PD-L1 and CDK4/6. Given the predilection for brain metastases in this population, there is enthusiasm to identify the optimal combination of effective treatments. Tucatinib, capecitabine, and trastuzumab combination represent one such promising strategy. With the increasing longevity of these patients, important clinical questions include optimal treatment sequencing, the role of de-escalation of treatment in excellent responders, and the associated financial toxicity. Despite the aggressive nature of this subtype of breast cancer, the outcomes continue to improve for these patients with the evolving treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, USA.
- Department of Internal Medicine, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, USA.
- Division of Hematology-Oncology, University of Massachusetts Chan Medical School - Baystate, Springfield, MA, USA. Prarthna.bhardwaj@baystatehealth.org.
Zitieren
APA
Avelino, A. R. M., Pulipati, S., Jamouss, K., & Bhardwaj, P. V. (2024). Updates in Treatment of HER2-positive Metastatic Breast Cancer. Current Treatment Options in Oncology, 25(12), 1471-1481. https://doi.org/10.1007/s11864-024-01277-2
Vancouver
Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Current Treatment Options in Oncology. 2024;25(12):1471-1481. doi:10.1007/s11864-024-01277-2
BibTeX
@article{Avelino2024,
author = {Avelino, Alzira R M and Pulipati, Soumya and Jamouss, Kevin and Bhardwaj, Prarthna V},
title = {Updates in Treatment of HER2-positive Metastatic Breast Cancer},
journal = {Current Treatment Options in Oncology},
year = {2024},
volume = {25},
number = {12},
pages = {1471--1481},
doi = {10.1007/s11864-024-01277-2}
}
EUVIMED